Evidence map›Paper›PMID 33428678›Full record

ArticlePloS one2021

Reno-protective effect of IL-34 inhibition on cisplatin-induced nephrotoxicity in mice.

Yukihiro Wada, Masayuki Iyoda, Kei Matsumoto, Taihei Suzuki, Shohei Tachibana, Nobuhiro Kanazawa, Hirokazu Honda

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yukihiro WadaDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.ORCID 0000-0001-5996-8735
Masayuki IyodaDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Kei MatsumotoDivision of Nephrology, Department of Medicine, Showa University Koto Toyosu Hospital, Tokyo, Japan.
Taihei SuzukiDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Shohei TachibanaDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Nobuhiro KanazawaDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Hirokazu HondaDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInterleukin-34 (IL-34) shares a receptor (cFMS) with colony stimulating factor-1 (CSF-1), and these two ligands mediate macrophage proliferation. However, in contrast to CSF-1, the influence of IL-34 on tubular epithelial cells (TECs) injury remains unclear. We investigated the physiological effects of IL-34 on TEC damage caused by cisplatin nephrotoxicity (CP-N).

methodsMice were administered anti-mouse IL-34 antibody (anti-IL-34 Ab; 400 ng/kg) or vehicle from 1 day before and up to 2 days after CP-N induction. In vitro, mouse renal proximal TECs (MRPTEpiC) were cultured to analyze the inhibitory effects of IL-34 on CP-induced TEC apoptosis.

resultsCompared to vehicle treatment, anti-IL-34 Ab treatment significantly suppressed the intra-renal expression of IL-34 and its two receptors, cFMS and PTP-ζ, and significantly improved renal function, ameliorated tubulointerstitial injury, suppressed macrophage infiltration, and reduced apoptotic cell numbers in CP-N mice. It also significantly reduced the renal transcript levels of Kim-1, MIP-1/CCL3, TNF-α, and Bax in CP-N mice. Furthermore, anti-IL-34 Ab-treated CP-N mice showed less renal infiltration of F4/80+TNF-α+ cells. In vitro, stimulation with CP induced the expression of IL-34 and its two receptors in MRPTEpiC. Anti-IL-34 Ab treatment significantly suppressed CP-induced Bax expression with the degradation of ERK1/2 phosphorylation in damaged MRPTEpiC.

conclusionsIL-34 secreted from damaged TECs appeared to be involved in the progression of CP-N. Inhibition of IL-34 with neutralizing antibody directly prevented CP-induced TEC apoptosis by inhibiting the phosphorylation of ERK 1/2. Blocking of IL-34 appears to suppress the proliferation of cytotoxic macrophages, which indirectly attenuates CP-N. Thus, IL-34 represents a potential therapeutic target for TEC injury, and the inhibition of IL-34 might have a reno-protective effect.

Indexed as

AnimalsAntibodiesAntineoplastic AgentsApoptosisCells, CulturedCisplatinInterleukinsKidney DiseasesKidney Tubules, ProximalMaleMiceMice, Inbred C57BLProtective AgentsAntibodiesAntineoplastic AgentsCisplatininterleukin-34, mouseInterleukinsProtective Agents

Identifiers

PMID33428678
PMCPMC7799787

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.